FLuticasone in cOvid Treatment (FLOT)

Summary

A multicenter, open-label, randomized controlled trial to evaluate the efficacy of fluticasone propionate (metered dose inhaler - MDI) added to standard care at early stage of COVID-19 in reducing the incidence of adverse outcomes (any of those following: oxygen therapy, systemic corticosteroids, hospitalization, mechanical ventilation, and mortality) in symptomatic patients either from 18 to 49 years of age with risk factors or older than 50 years.

Timeline

Start

2021-09-22

Primary completion

2022-01-31

Completion

2022-08-30

Drugs

Indications